We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

48 hedge funds and large institutions have $9.42M invested in Celldex Therapeutics in 2019 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more call options, than puts

Call options by funds: $91K | Put options by funds: $39K

7% more capital invested

Capital invested by funds: $8.8M → $9.42M (+$622K)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2.66% less ownership

Funds ownership: 26.42% → 23.76% (-2.7%)

11% less funds holding

Funds holding: 54 → 48 (-6)

23% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 13

40% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 10

Holders
48
Holders Change
-6
Holders Change %
-11.11%
% of All Funds
0.95%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
10
Reduced
13
Closed
10
Calls
$91K
Puts
$39K
Net Calls
+$52K
Net Calls Change
+$23K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$207K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$49.3K
3
Citadel Advisors
Citadel Advisors
Florida
+$36.5K
4
Morgan Stanley
Morgan Stanley
New York
+$27.2K
5
Simplex Trading
Simplex Trading
Illinois
+$22.1K

Top Sellers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
-$162K
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$36K
3
VF
Virtu Financial
New York
-$30K
4
PPA
Parametric Portfolio Associates
Washington
-$23K
5
HighTower Advisors
HighTower Advisors
Illinois
-$21K
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
26
Tower Research Capital (TRC)
New York
$11K +$5.34K +2,303 +93%
PAM
27
Panagora Asset Management
Massachusetts
$4K – – –
UBS Group
28
UBS Group
Switzerland
$3K -$7.5K -3,232 -68%
FDCDDQ
29
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.37K – – –
LTFS
30
Ladenburg Thalmann Financial Services
Florida
$2K -$1.39K -599 -36%
GWM
31
Geneos Wealth Management
Colorado
$2K – – –
Royal Bank of Canada
32
Royal Bank of Canada
Ontario, Canada
$1K -$195 -84 -15%
AG
33
Advisor Group
Arizona
$1K – – –
VFA
34
Valeo Financial Advisors
Indiana
$1K +$1.54K +666 New
KFS
35
Kelly Financial Services
Massachusetts
$103 – – –
BNP Paribas Financial Markets
36
BNP Paribas Financial Markets
France
$54 -$538 -232 -91%
EW
37
Evoke Wealth
California
$18 – – –
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
– -$36K -16,719 Closed
VF
39
Virtu Financial
New York
– -$30K -13,993 Closed
HighTower Advisors
40
HighTower Advisors
Illinois
– -$21K -11,275 Closed
PPA
41
Parametric Portfolio Associates
Washington
– -$23K -10,657 Closed
RIA
42
Realta Investment Advisors
Delaware
– -$4K -1,925 Closed
Victory Capital Management
43
Victory Capital Management
Texas
– -$4K -1,796 Closed
BWP
44
BSW Wealth Partners
Colorado
– -$1K -448 Closed
Bank of America
45
Bank of America
North Carolina
– -$100 -43 -17%
TCWM
46
Total Clarity Wealth Management
Illinois
– +$19 +8 New
Fidelity Investments
47
Fidelity Investments
Massachusetts
– +$70 +30 +150%
NFG
48
Next Financial Group
Texas
– +$93 +40 New
Bank of Montreal
49
Bank of Montreal
Ontario, Canada
– +$139 +60 New
RMAM
50
Raab & Moskowitz Asset Management
New Jersey
– +$153 +66 New
1
2
3

CLDX Hedge Fund Activity: Q4 2019 in Review

48 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2019, worth a combined $9.42M — up 7.1% from $8.8M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of CLDX and 6 opened new positions — a net loss of 4 holders — while 13 trimmed existing stakes and 10 added.

The largest buyer was Renaissance Technologies, adding an estimated $207K. The largest seller was Bridgeway Capital Management, cutting an estimated $162K.

  • 48 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2019, down from 54 in Q3 2019.
  • Funds reported $9.42M of Celldex Therapeutics stock for Q4 2019, up 7.1% quarter-over-quarter.
  • 6 funds opened new Celldex Therapeutics positions in Q4 2019 and 10 closed out, a net change of -4 holders.
  • The largest Celldex Therapeutics buyer in Q4 2019 was Renaissance Technologies, an estimated $207K added.
  • The largest Celldex Therapeutics seller in Q4 2019 was Bridgeway Capital Management, an estimated $162K sold.

Based on aggregated 13F filings for Q4 2019.